Get Real: Talking mental health & disability
Get Real presents frank and fearless conversations about mental health and disability, including people with lived experience, frontline workers in the sector, as well as policymakers and advocates. Get Real is produced and hosted by Emily Webb and co-hosted by Karenza Louis-Smith on behalf of ermha365 Complex Mental Health and Disability Services provider (https://www.ermha.org/).
Get Real: Talking mental health & disability
Psychopharmacology for complex needs with Forensic Psychiatrist Dr Danny Sullivan
This is another conversation from the Complex Needs Conference 2025 and our guest is Adjunct Associate Professor Danny Sullivan, Consultant Forensic and Adult Psychiatrist.
Dr Sullivan gave a keynote at the conference about the prescribing of psychotropic medications, which are namely drugs that influence a person's mood, thoughts, and behavior - for people with complex needs.
He is the Board Director of ACSO Australia and Director of Victoria's Sentencing Advisory Council.
This episode was recorded at the Complex Needs Conference in Melbourne co-hosted in March 2025 by ermha365 and ACSO Australia with support from Swinburne University's Centre for Forensic Behavioural Science and funded by the Victoria State Government's Department of Families, Fairness and Housing.
ermha365 provides mental health and disability support for people in Victoria and the Northern Territory. Find out more about our services at our website.
Helplines (Australia):
Lifeline 13 11 14
QLIFE 1800 184 527
13 YARN 13 92 76
Suicide Callback Service 1300 659 467
ermha365 acknowledges that our work in the community takes place on the Traditional Lands of many Aboriginal and Torres Strait Islander Peoples and therefore respectfully recognise their Elders, past and present, and the ongoing Custodianship of the Land and Water by all Members of these Communities.
We recognise people with lived experience who contribute to GET REAL podcast, and those who love, support and care for them. We recognise their strength, courage and unique perspective as a vital contribution so that we can learn, grow and achieve better outcomes together.
Get Real is recorded on the unceded lands of the Boon, wurrung and Wurundjeri peoples of the Kulin Nation. We acknowledge and pay our respects to their elders, past and present. We also acknowledge that the First Peoples of Australia are the first storytellers, the first artists and the first creators of culture and we celebrate their enduring connections to country knowledge and stories, celebrate their enduring connections to country.
ermha365:Knowledge and stories. Welcome to Get Real talking. Mental health and disability brought to you by the team at Irma 365.
Dr Danny Sullivan :Join our hosts, Emily Webb and Carenza Louis-Smith, as we have frank and fearless conversations with special guests about all things mental health and complexity conversations with special guests about all things mental health and complexity.
ermha365:We recognise people with lived experience of mental ill health and disability, as well as their families and carers. We recognise their strength, courage and unique perspective as a vital contribution to this podcast so we can learn, grow and achieve better outcomes together.
Emily Webb:Welcome to Get Real talking mental health and disability. I'm Emily Webb. We are bringing you another conversation from the Complex Needs Conference and our guest is Adjunct Associate Professor Danny Sullivan, who is a consultant, forensic and adult psychiatrist. I was pleased to grab some time with Danny, who gave a keynote at the conference about prescribing psychotropic medications, which are namely drugs that influence mood, thoughts and behaviour for people with complex needs. Danny has a tonne of experience in forensic mental health and held senior roles at the Victorian Institute of Forensic Mental Health or Forensic Care and provides medico-legal and complex case assessments in criminal, coronial, child protection and other Australian cases. Danny is also the board director of AXA Australia, who co-hosted the Complex Needs Conference with ERMA 365. In 2024, danny was appointed director of Victoria's Sentencing Advisory Council.
Emily Webb:We cover a fair bit in this conversation, including the challenges of prescribing for people with multiple diagnoses, the issue of off-label prescribing, where medications are used for indications not licensed by the Therapeutic Goods Administration, and resources and programs available for those supporting people with complex needs to get the right medication. Dr Danny Sullivan, it's so good to have some time with you at the Complex Needs Conference, so we're recording live and you've been here for both days. It's day two, danny. Can you first of all tell us about your work? You're a forensic psychiatrist, where you work, where you've worked and why you've come to the conference?
Dr Danny Sullivan :Well, forensic psychiatry, emily, is obviously psychiatry but applied to people who are in prison or who have offended or who are at risk of offending and who have mental health and related issues like personality disorder and substance use are the main two. I trained in England and Australia. I've worked over the last 20 years in the public mental health system. I work in Victoria. I do a little bit of work in the Northern Territory as well. I work in Victoria. I do a little bit of work in the Northern Territory as well. Most of that work has been in the community, so assessing and providing treatment to people who are at risk of offending or have offended. Some of that has also been in hospitals, in the secure hospital in Victoria and also in prisons, in most of the Victorian prisons.
Emily Webb:Well, you're certainly doing pretty tough work, and you know, in the public system, which I always think is to be commended, but it's not easy. You're speaking at the conference and we're going to actually talk a bit about what you're covering, just so other people can hear it. What's your topic that you're talking about?
Dr Danny Sullivan :well, I chose to talk about the medication that's used for people with complex needs. So that's not necessarily medication that's used for people with complex needs. So that's not necessarily medication that's used for a particular diagnosis. It's when people are trying to treat a difficult behaviour or aggression or substance use or other problems. And, in fact, once I developed the presentation, I realised that most of what I was going to be talking about was the limited range of medications for which there is effective evidence and also the ways in which prescribing those medicines can be really problematic.
Emily Webb:I find it really interesting to know about who can prescribe and who can't. I mean generally, I think people understand that doctors prescribe medication. Psychiatrists are the only people who can prescribe the kind of medication for, I guess, mental health conditions. Is that correct? Just so people listening who may not know about this can understand.
Dr Danny Sullivan :No, plenty of GPs can prescribe those medications too, and increasingly nurse practitioners. But I suppose when it comes to complicated medications, high doses, people with very serious problems, many prescribers would become anxious and would like to have a psychiatrist just having oversight of the prescribing, giving advice, checking in that the dosages and the indications were correct. The use of medication in complex needs, unfortunately, is often driven by crisis. It occurs in the emergency department, it occurs when someone's behaviour is destructive of property or is damaging to people, and usually when the person is being assessed they're not in the best of moods, they don't particularly give a good account of themselves. So I'd describe that as very reactive prescribing rather than. So I'd describe that as very reactive prescribing rather than prescribing which is considered and thoughtful and in which there's a discussion about what's to be done and there's some input from the person.
Emily Webb:So, with the medications that you're talking about and their uses, I guess, for complex needs, what are we talking about when we're saying complex needs? We've got a lot of people at this conference and complexity is the name of the game here, and it's mental health conditions, it's disability, but it's a lot of other things like barriers to you know, living the kind of lives they want. But in your role as a psychiatrist, what kind of conditions, or I don't know if that's the right word what are you?
Dr Danny Sullivan :prescribing for. Well, we talk about complex needs as involving usually a mental health diagnosis or a personality disorder. That can be intellectual disability or acquired brain injury. Often there's complications with substance use as well as that, I think with complex needs we're often talking about people whose needs aren't met by one service, so sometimes they're described as boundary spanners or intersectional.
Dr Danny Sullivan :So we're talking about, I suppose, people whose contact with various services is unfulfilling and often challenging. They can be argumentative, not turn up to appointments, not be eligible for services because of the range of diagnosis. They have To give an example. I mean, if you attend a service and you're aggressive and finger-pointing and threatening, I reckon the clinicians who are going service and you're aggressive and finger-pointing and threatening, I reckon the clinicians who are going to see you will find any reason they can to determine that you should go to another service because you know, in frank terms, they don't like you. So in this case we're talking about the medications that are prescribed to people who have multiple diagnoses, and they're medications which aren't necessarily for their primary mental health problem, but they're medication which is at some level intended to assist with the behaviours that they present with and which cause problems.
Emily Webb:So with your presentation, why are you talking about this, what are you wanting the people in the room to understand, and how did you get to this place where you're like? I want to talk about this.
Dr Danny Sullivan :Well, it's interesting. At this Complex Needs Conference, by my estimation there's only one other psychiatrist out of a large number of people attending. I figured that a lot of people would talk about interesting services and approaches to complex needs that were at the service level and I wondered how my talk could be slightly different, and that's why I seized upon the idea of talking about medication. So even though many of the people here are not prescribers, they will have a passing acquaintance with lots of complicated medications. They will often have clients whose drug charts are full of medications and which might be causing problems. So I suppose I wanted to open people's eyes up to thinking about what to do about prescribing or when to prescribe or not to prescribe. Although I started off really wanting to get a grip on the contemporary landscape, I found myself increasingly focusing upon the limitations of evidence and the problems with prescribing and what we can do about it, and the problems with prescribing and what we can do about it.
Emily Webb:So what have you found are the limitations in the evidence and, I guess, the effectiveness of these drugs? From your experience as a psychiatrist, you've been doing this for many years, right?
Dr Danny Sullivan :Yeah, well, in Australia the Pharmaceutical Benefit Scheme is the subsidised medications which are provided. They're overseen by the Therapeutic Goods Administration. That government, federal government body assesses medications to determine if they're safe and effective. It publishes information about them. It does a health technology assessment, which is really to determine whether there is sufficient evidence to justify paying for the medication, because of course, the pharmaceutical benefit scheme subsidises expensive medications so that consumers don't have to pay the full cost, like they would in, say, the United States. And finally, it monitors medications once they've been introduced to the market to check that they're not causing unforeseen adverse effects or other problems.
Emily Webb:And the kind of medications that you are talking about. What are some of the names of them that people might have heard of?
Dr Danny Sullivan :Well, they tend to be what we call psychotropic medications, medications that affect mental health. So they're anti-psychotic medications, they're anti-depressants, they're medications prescribed for anxiety, some other types of medication Mood stabilizers is perhaps a good example and on the pharmaceutical benefits scheme, every medication has a range of licensed indications. What that means is that the Therapeutic Goods Administration, the TGA, has said this medication shows evidence that it is effective in the treatment of something. I'll give you an example. A medication called Risperidone is used for schizophrenia, it's used for mania in bipolar affective disorder, but it's also used for behavioural disturbance in people with dementia. It's used for behavioural disturbance and aggression in people with intellectual disability who are children, and it's used in behavioural disturbance in autism spectrum disorders. They're licensed indications. What that means is that there is published research which satisfies the TGA that those medications are safe and effective to use. But there are other medications which are going to be used for those same indications which are not licensed. So if it's not licensed, we call that off-label prescribing.
Emily Webb:So can you prescribe? You can prescribe off-label stuff, but it's going to cost you more.
Dr Danny Sullivan :Well, that's right. If it's not for the licensed indication, you can't get the pharmaceutical benefit scheme price, and that's really interesting. Pharmaceutical benefit scheme price and that's really interesting. An antipsychotic medication might cost an employed person around $30. There might be an added fee from the pharmacy. For a person with a healthcare card it might only cost just under $4. But if it's prescribed off-label, the cost of that per month can be $200 or $300 per month. So that's a very significant cost to the consumer. So off-label prescribing is when a medication is used for an indication that it's not licensed for, when it's used at a different dose, when it's administered by a different method, when it's used for a longer period than it should be, or if it's used for a person whose age or gender is not consistent with the licensing.
Emily Webb:And so are you forming the thought or the pitch in your presentation that there needs to be more research for off-label use, or that the PBS, the TGA, needs to loosen up a bit Like what conclusions have you come to through your experience and the research you've done?
Dr Danny Sullivan :Yeah, look, it's a really good point. I mean, there certainly is a need for more research, and some of the people with complex needs would never be included in a research study, because what you really want is someone who's got a pure disorder and it's not confounded or confused by other things such as substance use or other problems. So with off-label prescribing, we certainly need more evidence to justify its use, but actually most of the findings were that the processes by which we prescribe off-label and the indications for which we prescribe may expose the people who take the medication to not insignificant risks.
Emily Webb:So can you tell me a bit more about that? Because I guess there's side effects for everything, but I do have a basic understanding that there are some drugs that can be quite effective, but they do have significant side effects and that's got to be balanced.
Dr Danny Sullivan :Yeah, so we use off-level prescribing when a standard treatment hasn't improved the symptoms, but the guidance is pretty clear.
Dr Danny Sullivan :The Royal Australian and New Zealand College of Psychiatrists has guidance on how to prescribe and it says, for instance, that we need to get informed consent.
Dr Danny Sullivan :So the person we're prescribing for needs to understand that this is not a licensed indication and they need to be able to participate in the decision-making process and hear about the risks and benefits and have the opportunity to ask questions before they prescribe the medication and in complex needs, I think often the prescription is done to someone rather than with them.
Dr Danny Sullivan :When a person doesn't have capacity to give informed consent, there needs to be a legal framework, and it could be that, for instance, they're a compulsory patient under the Mental Health and Wellbeing Act. It could be that there's a legal guardian in place, or it could be that they're a child and their parent is their legal guardian. So that's really important. What's most interesting is that there is a requirement, according to the College of Psychiatrists, that a psychiatrist prescribing off-label seeks a peer review. What that means is a second opinion from another psychiatrist or that they discuss it with other psychiatrists. They discuss the non-identifying but specific details of the case to get guidance in that prescribing and I think that's actually quite burdensome and I don't think it's actually very often done.
Emily Webb:So if a psychiatrist is prescribing off-label, how do they go about it? Is prescribing off-label, how do they go about it? How should they go about it?
Dr Danny Sullivan :Well, I mentioned the need to involve the patient in the discussion, but, moreover, there should be a really clear definition of what it is that the prescription is intended to do, and then there should be monitoring of that medication and of its potential benefits to see that in fact, it does what we hoped it would do. The patient needs to be reviewed regularly, preferably by the same psychiatrist, so that they can monitor the effectiveness of the prescription. And for people with complex needs who are, say, in a residential facility say someone with a disability what you'd hope is that the residential staff are collecting data which can actually inform the decision. So I'll give you an example.
Dr Danny Sullivan :Let's say we talked about that medication, risperidone. Let's say that someone wanted to prescribe that to reduce aggressive behaviour in autism spectrum disorder. You might, for instance, say how many incidents of aggressive behaviour are there per week over the six months before I start the prescription and then over the next three months? Can I demonstrate a reduction? And if I change the dose, if, for instance, I increase the dose, do I see a further reduction? Finally, in addition to that, other observed side effects that I can expect with risperidone might occur, and are those severe enough that, in fact, I should stop the prescription because the side effects are worse than the actual treatment.
Emily Webb:So, in effect, yourself psychiatrists do need some buy-in from people who are supporting people with complex needs. There needs to be education around how to, I guess, monitor how the medication's going and understanding what the medications are.
Dr Danny Sullivan :Oh, absolutely. And particularly many people with complex needs, particularly those who have a cognitive impairment, aren't initiating the contact with a service themselves. They're looked after, they're in care, or someone else is making the appointment, someone else is taking them there, someone else is commenting and providing information to the prescriber. So those people are, by definition, more vulnerable. They have less voice and they rely upon staff to speak for them. What that also means is that they rely upon staff to look at their drug chart and say hang on, there's a lot of medication here, what is this for? And to go to the prescriber and say look, I'm a bit worried because, for instance, I observed that she's always asleep during the day, or she's gained 20 kilograms over the last four months since we started this medication, or I noticed that she's having epileptic seizures more frequently than she did beforehand. That's an example, I suppose, of the role of staff advocating for and supporting their clients.
Emily Webb:In your experience. Does that happen more often than not, or is it the other way around?
Dr Danny Sullivan :I think staff often feel very disempowered dealing with the medical profession. Obviously, they're at a disadvantage in terms of knowledge and some in the medical profession might not take to being challenged on a particular prescription. But as well as that, I think it's difficult when you've got a person with very complex needs. It's really hard to access a service consistently which will provide them with ongoing care and follow-up. Often, as I said, you end up with very reactive, crisis-driven presentations. You don't get to see the same, for instance, psychiatrist, at a regular interval.
Emily Webb:So let's talk about the evidence, or the lack of evidence, for the effectiveness of some of the drugs that are prescribed for conditions that come under the complex needs banner. Let's talk about the treatment of substance use disorder.
Dr Danny Sullivan :Okay, well, there's some really strong evidence. So, for instance, for opioids like heroin, we know that long-acting injectable antipsychotic medications like buprenorphine are really effective and they reduce the rate of relapse and they're tolerated well by patients. That's almost overtaken the previous sublingual or under the tongue formulations, or oral methadone, and it's preferable to patients because it's injected once a week or once a month and apart from some discomfort it's a really effective treatment. So that reduces not just opioid use but also risk of death by overdose.
Dr Danny Sullivan :For cannabis, we don't have any licensed medications. There is no evidence of any medication being effective to treat cannabis dependence. For alcohol, we have a couple of medications that have some strong evidence naltrexone perhaps less so for acamprosate, and there's another medication called disulfiram which can be used in some cases, but all other treatments don't show any evidence that if you give them to a person with alcohol dependence it reduces the likelihood that they're drinking at high levels or it enables them to stay off the grog. There's a few medications which are trialled, but there isn't actually sufficient evidence yet. People will have heard of the weight loss drugs like Ozempic or Wegovi. I'm sure there's different ways of pronouncing them, but semaglutide is the is the technical name and they're called glp1 agonists. They're used for diabetes, so that the weight loss indication is a secondary aspect, but they've also shown in people who are taking those drugs that they lose interest in alcohol, and people drinking at high levels now drink less. There's a few other medications which also show some promise, but there isn't sufficient evidence to prescribe them yet.
Emily Webb:I guess with the use of Ozempic for weight loss it would probably be pretty hard to get your hands on it. To maybe try it for alcohol use.
Dr Danny Sullivan :Yeah, that's right. The other issue is, for instance, for things like methamphetamine or cocaine. There's been trials of a whole range of different medications but none have shown any effectiveness. When I say trials of a lot of medications, maybe 20 medications have been trialed experimentally. That is, you randomize people to either the medication or to a placebo and then you monitor over time whether they've still got methamphetamine or cocaine in a urine drug screen and you see whether the population given the drug you think might work shows a greater proportion of people who are able to cease it. So no medication has proven effective in sustaining abstinence from stimulants.
Emily Webb:So you mentioned that there's no drug at the moment that's shown to be effective to treat cannabis misuse, but medicinal cannabis is actually prescribed a lot more in Australia, so how does that work?
Dr Danny Sullivan :Well, the Therapeutic Goods Administration says that there's no evidence for the use of cannabis for neuropsychiatric disorders, except a few very rare cases.
Dr Danny Sullivan :So spasticity as a neurological condition, some varieties of severe chronic pain, a rare epilepsy syndrome, nausea and vomiting induced by chemotherapy, and maybe for extreme weight loss in HIV. So there's a little bit of evidence for those indications and it's certainly licensed for that. So there's a little bit of evidence for those indications and it's certainly licensed for that. But the people who are taking it for anxiety, for insomnia, are not based on any clear evidence base. Furthermore, the formulations of medicinal cannabis that are in the market have very variable quantities of the active ingredients. As a result, what that means is you really can't study it very effectively. In particular, we know that for those who are prone to developing a psychotic illness, the rate of psychosis increases fivefold if you're using high potency cannabis. So in my practice what I'm seeing are patients who have very severe schizophrenia, who are admitted to hospital numerous times per year, who are very disabled, and they are obtaining separately a script for medicinal cannabis which is directly contraindicated and really bad for their mental health.
Emily Webb:So how are they obtaining that? Is it through a practitioner or is it sort of off the books?
Dr Danny Sullivan :Well, I think the issue is that a market has sprung up of people who are prescribing purely cannabis. You would go to them for a cannabis prescription, but it's not being prescribed as part of the normal armamentarium of drugs by people who are prescribing other things for mental health as well.
Emily Webb:So what about medications that can help with violent behaviour or harming oneself? Is there anything that can be effective in your experience?
Dr Danny Sullivan :Well for people with complex needs. This is a really big problem, emily. Firstly, in Australia there is no medication licensed for aggression or self-harm except, as I mentioned, risperidone, for a very limited group of people. There's some evidence for medication you prescribe for depression. There's some evidence for other antipsychotics. There's some evidence for mood stabilisers and anti-epileptic drugs, but all of these the evidence is not supported sufficiently for the medication to be licensed for it. So all prescription for that is described as off-label For people with disability or mental health problems. In fact it's defined in the legislation as chemical restraint. What that means is not that you can't prescribe it, but that you have to report on the prescribing of it. It has to be documented, reported to government and they monitor and oversight it.
Emily Webb:It all sounds pretty complicated, to be honest, from my non-medical perspective. So it must be extremely challenging to be working in this space, because you're trying to help people ultimately, aren't you?
Dr Danny Sullivan :Well, that's right and there's a culture of perhaps a very large culture in Australia of off-label prescribing and it's certainly driven by optimism that maybe medication can help people. But, as I've said, with the restrictions on off-label prescribing I think it does pose quite significant risks to numbers of patients and also the evidence of a benefit is not necessarily clear. So that places a really big burden on prescribers to be safe, places a burden upon staff looking after vulnerable clients and advocating for them to really monitor for those issues and come back. And of course there's a bit of a split interest there, because the staff looking after a person with complex needs also want to see a reduction in problem behaviours or a reduction in issues which led them to seek the prescription in the first place problem behaviours or a reduction in issues which led them to seek the prescription in the first place.
Emily Webb:It's complicated, as they say. It sounds very complicated and a lot of, I guess, red tape around it. So what kind of adverse outcomes, side effects, are you talking about?
Dr Danny Sullivan :Okay. Well, lots of these medications, particularly ones prescribed to reduce aggression, are very sedative. Some of those sedative medications actually impact upon your thinking. They can make you mentally sluggish and a bit dopey. In elderly people, in people with intellectual disability and in dementia, that can actually be the tipping point between being independent and being non-independent. They pose a risk of increasing your likelihood of falls. For people vulnerable to swallowing problems, they can actually cause swallowing problems which in rare cases are associated with death. They can cause metabolic problems like diabetes, high blood pressure, high cholesterol, significant weight gain. Some of the medications, particularly for schizophrenia, which are used for other purposes, can cause severe and often lifelong movement disorders, and a number of these medications increase the risk of seizures in those who are prone to them.
Emily Webb:And so, with everything that we've spoken about and what you're going to present about and that you've researched, what do you think needs to happen? Like, what would you like to be the Disney magic wand solution? We know there's not one, but where do we need to head?
Dr Danny Sullivan :It's an Australia-wide problem of the culture of prescribing, so we need to really stick to those guidelines and sort of. I suppose, have an increased level of suspicion and concern about prescribing where there is no licensed indication. I think we need to do the research so actually monitor the outcomes and develop the evidence base that, in fact, might convert some of these uncertain prescriptions into ones for which there is an evidence base. But most of all, I think we need to have a system that ensures there's provision for adequate follow-up and for clarity of prescribing.
Dr Danny Sullivan :What do I hope to achieve prescribing this medication? And for clarity of prescribing? What do I hope to achieve prescribing this medication? How will I know if it's been effective and when will I choose to stop it on the basis that it's ineffective? As I said earlier, if your prescribing is crisis driven, every time there's a crisis, a new medication is added or the dosage of one is bumped up. But every time there is no crisis for a period of a week or two weeks, that doesn't mean that the medication is then ceased or the dosage is reduced. So what we have is this sort of continual drive to treat challenging behaviour, which can lead to a person being exposed to significant numbers of medications, high dosages and, consequently, significant adverse effects.
Emily Webb:And for consumers and carers people who care for people with complex needs, but also for the person who is getting prescribed the medication themselves. What can they do to, I guess, understand more, if that's a possibility, but advocate for themselves in a way that is going to mean that you're working with your clinician rather than just being told what's going to happen?
Dr Danny Sullivan :That's an interesting question. There are a range of opportunities set up by government to assist those supporting people with complex needs to get the right medication. So, for instance, the National Disability Insurance Scheme provides for home medicines review, which is where a person on five medications or more and who has NDIS funding can go to a pharmacist and have them review their drug chart and advise on the possibility of drug interactions, advise on whether some medications can be reduced or ceased and also advise on the potential for some drugs to interact with others ceased and also advise on the potential for some drugs to interact with others In aged care. There are guidelines on the prescription of psychotropic medications in aged care facilities. All health services which are accredited by the Australian Commission on Safety and Quality in Healthcare now have to ascribe to a standard which is called psychotropic Medicines in Cognitive Disability or Impairment.
Dr Danny Sullivan :But perhaps the most impressive innovation in this comes from the United Kingdom and it's called STOMP, which is Stopping the Over-Medication of People with a Learning Disability in Autistic People. That didn't translate to a very good acronym, but STOMP is really effective and there's an Australian version called STOMPOZ, that's S-T-O-M-P-O-Z. What that is? It involves a range of resources for those supporting people, usually with a disability. It involves prescribers making a commitment to reviewing medications and deprescribing where possible, particularly where there is not strong evidence for the use of a medication For services that have signed up to it. I think it provides a framework for really effective shared decision-making around medication for people whose voice is often not heard.
Emily Webb:So, danny, this has been a really interesting chat. How have you been finding the conference so far?
Dr Danny Sullivan :It's a really good opportunity for networking. The people here are special. They've chosen to work in really complicated and difficult areas. They're not sort of areas that earn people lots of money, but there's a lot of love and there's a lot of good feeling about doing healthy things for people that John Fain described yesterday as having been left behind, and I think that vibe is through the whole conference. I think the presentations are really top quality. I think Irma and AXO have done a great job in putting this together and being supported by government to do so.
Emily Webb:Well, danny, thank you so much for your time, because I know it's limited and we're really grateful that you came on and talked about what you did, so hopefully we'll speak to you again.
Dr Danny Sullivan :It's been a pleasure.
ermha365:Thanks, emily. You've been listening to Get Real talking mental health and disability, brought to you by the team at Irma 365. Get Real is produced and presented by Emily Webb with Corenza Louis-Smith and special guests. Thanks for listening and we'll see you next time.
.jpg)
